TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03465943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer
Description: 1L of Ringer's solution as a preload in one group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer
Description: 1L of Ringer's solution as a preload in one group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven
Description: 500 ml of voluven will be given in combination with 500 ml Ringer's solution as a preload in the other group.
Study: NCT03448536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium, (Aleve, BAY117031)
Description: 220 mg \*2 tablets, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium, (Aleve, BAY117031)
Description: 220 mg \*2 tablets, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (Tylenol Extra Strength)
Description: 500 mg \*2 caplets, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (Tylenol Extra Strength)
Description: 500 mg \*2 caplets, orally, single dose
Study: NCT01403649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Private/public collaboration to increase flu vaccination
Description: Intervention practices will develop office-based interventions including methods to identify high-risk patients within their practices and methods of maximizing the immunization of these children within the practice, use of patient reminders, after-hours influenza clinics, walk-in provision of influenza vaccine and increased focus on education regarding the need for immunization. The practices will also collaborate with their county public health departments and visiting nursing associations to develop private-public collaborative interventions that may include large clinics for school-aged children for multiple practices and tracking of influenza supplies and redistribution of influenza vaccine between practices when supplies are delayed or inadequate.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: This group will continue administering influenza vaccine to their patients in their practice as they normally do.
Study: NCT01493037

Intervention type: DEVICE
Group type: OTHER
Intervention: PICSO (Pressure-controlled Intermittent Coronary Occlusion
Description: The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.
Study: NCT05144399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated antibiotic treatment
Description: E. faecalis uncomplicated: 4 weeks.~E. faecalis complicated: 4 weeks.~S. aureus uncomplicated: 2 weeks.~S. aureus complicated: 4 weeks.~Streptococci spp. NVE: 2 weeks.~Streptococci spp. PVE or abscess: 3 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 1 week after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment length
Description: E. faecalis uncomplicated: 6 weeks.~E. faecalis complicated: 6 weeks.~S. aureus uncomplicated: 4 weeks.~S. aureus complicated: 6 weeks.~Streptococci spp. NVE: 4 weeks.~Streptococci spp. PVE or abscess: 6 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 2 weeks after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis.
Study: NCT01582698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN 0.5 ml
Description: Solution/suspension for injection (intramuscular injection into the deltoid muscle of the right or left upper arm). Dosage frequency of booster vaccination: dependent on serum TBE antibodies.
Study: NCT01335945

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryoablation
Description: All subjects will receive cryoablation of the celiac plexus with Galil Medical cryoablation systems and needles under imaging guidance.
Study: NCT04016116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib po days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib po days 1-21
Study: NCT02781649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1200 mg/d (\> 75 kg) or 1000 mg/d (\< 75 kg) by mouth daily in two divided doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg daily
Study: NCT02568670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical signs
Description: to remove the peripheral venous catheter according clinical signs
Study: NCT01722747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)
Description: A 7-month intervention was conducted over one academic year \& included the following core components: 1. A Lead Teacher (LT) in each school was appointed and trained to facilitate the program on-site; 2. A tobacco policy was implemented; 3. Study health educators and LTs conducted group discussions with teachers addressing 6 intervention themes; 4. Materials; 5. Support for tobacco use cessation. Schools randomized to delayed intervention control condition did not receive any intervention until after final data collection, when they were given a 3-month shortened intervention.
Study: NCT02761447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Traditional and Imaginary Motor Program
Description: Amputees patients also conservative protocol will undergo physiotherapy techniques work Imaginary Motor. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases: a) relaxation of Benson, b) phase external imagination where cycles of normal running on a video provided by the physiotherapist, c) phase internal imagination where the patient will identify the problem discussed compared with the normal course presented in the video, d) recreation of images in the first person made an e normalized locomotion) closing his eyes, prompted the patient to mentally recreate sequences normal gait and analyzed and subsequently verbalize differences of these with respect to their own way of getting around.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Traditional and Mirror Therapy
Description: Amputees patients also conservative protocol will undergo physiotherapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
Study: NCT02762903

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TSA with tenotomy technique
Description: Standard procedure: Utilization of tenotomy for mobilization of subscapularis during total shoulder arthroplasty (TSA). The subscapularis tendon is incised close to its attachment on the humerus. The Tendon is repaired with sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TSA with lesser tuberosity osteotomy technique
Description: Standard procedure: Utilization of the osteotomy to mobilize the subscapularis during TSA. A small fleck of bone is removed from humerus, the subscapularis tendon is still attached. The fleck of bone is reattached with sutures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder prosthesis
Description: Standard procedure: Total shoulder arthroplasty replaces both components of the ball and socket joint with a metal device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder prosthesis
Description: Standard procedure: Total shoulder arthroplasty replaces both components of the ball and socket joint with a metal device.
Study: NCT02906722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous colimycin
Description: administration once, twice or 3 times per day according to renal function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous placebo
Description: administration once, twice or 3 times per day according to renal function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized colimycin
Description: Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized placebo
Description: Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
Study: NCT01568385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Study: NCT01292304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Oral administration once daily Dosage will range from 15 mg to 30 mg
Study: NCT01957540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Study: NCT02043743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: Stem Cells
Description: Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally 3-5 million MSCs injected into ovarian tissue.
Study: NCT05131802

Intervention type: DEVICE
Intervention: upper GIT endescopy
Description: Gastric mucosa alterations as erythema, bile existence in the stomach, gastric folds thickening, erosions, and petechiae were also recorded (Olympus single-channel CLK-4). Multiple biopsies were taken from gastric mucosa for histopathological study. Via Triple Lumen ERCP Cannula, 5 mL of gastric fluid was aspirated through the suction channel of the endoscope and collected in a sterile trap placed in the suction line, to be sent for analysis. Quantitative determination of gastric aspirate total bilirubin level was performed (Gen.3® kit and Cobas 8000 analyzer). The pH monitoring of gastric aspirate was performed during the gastroscopy just after collection with a glass electrode pH meter (Adwa®).

Intervention type: DEVICE
Intervention: upper GIT endescopy
Description: Gastric mucosa alterations as erythema, bile existence in the stomach, gastric folds thickening, erosions, and petechiae were also recorded (Olympus single-channel CLK-4). Multiple biopsies were taken from gastric mucosa for histopathological study. Via Triple Lumen ERCP Cannula, 5 mL of gastric fluid was aspirated through the suction channel of the endoscope and collected in a sterile trap placed in the suction line, to be sent for analysis. Quantitative determination of gastric aspirate total bilirubin level was performed (Gen.3® kit and Cobas 8000 analyzer). The pH monitoring of gastric aspirate was performed during the gastroscopy just after collection with a glass electrode pH meter (Adwa®).
Study: NCT02441868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shortness of breath recognition and treatment
Description: Hospice registered nurses will train family caregivers about how to recognize patient shortness of breath. This training will employ a guided learning tool the Respiratory Distress Observation Scale-Family. Training will be done with a DVD and return demonstration of the skills using the patient. In addition, the family will be taught the bundle of evidence-based interventions to treat shortness of breath.
Study: NCT04539223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Autoinjector 1-mL deliverable volume of 140 mg/mL
Study: NCT04147858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-2925
Description: NYX-2925 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-2925
Description: NYX-2925 administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally
Study: NCT02623660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ODIN1
Description: Shortly after surgery, electrodes will be applied to the lower extremity in such a way that the current will flow from the ankle through the knee replacement and pass through the thigh. The frequency of the treatments will vary over the period of time from post-op recovery to end of rehab.~All treatments are applying current that consists of different combinations of intensities within the micro to nano ampere ranges.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Device Testing
Description: Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic Device Testing
Description: Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.
Study: NCT00797888

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telephonic
Description: Between 4-8 phone calls each year for health behavior counseling to improve HbA1c

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephonic
Description: Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
Study: NCT00632502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin
Description: Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
Study: NCT04601636

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Prewarming
Description: Active prewarming with Flex Warming Gown (Bair Paws, 3M) for at least 30 minutes before induction of anesthesia, with active warming intraoperatively with Bair Hugger (3M)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Standard care with a passive prewarming (warm cotton blankets) before induction of anesthesia, with active warming intraoperatively with (Bair Hugger, 3M)
Study: NCT02675049

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline intranasally 45 min before surgery using a computer-generated random number table.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 1µg.kg-1
Description: dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 1.5µg.kg-1
Description: Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2µg.kg-1
Description: dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
Study: NCT03780010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: Dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
Study: NCT00966264

Intervention type: DRUG
Group type: OTHER
Intervention: LNG-IUS
Description: LNG-IUS releasing 25 microg of levonorgestrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS
Description: LNG-IUS releasing 25 microg of levonorgestrel

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hysterectomy
Description: operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Description: operation
Study: NCT04396847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin Oral Tablet
Description: Lorcasering 10mg Oral Tablet (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo Oral Tablet (BID)
Study: NCT02331199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amniotic fluid lamellar body count
Description: The LBC (the unit of measurement is number of lamellar bodies counted per microliter of amniotic fluid) will be determined using the platelet channels on the Hematology Flow Cytometer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal pulmonary artery Doppler
Description: A fetal pulmonary artery Doppler will be performed using color Doppler ultrasound. Doppler flow velocity measurements, including systolic/diastolic ratio, pulsatility index, resistance index, and acceleration-time/ejection-time ratio using spectral Doppler ultrasound.
Study: NCT03774290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680
Description: PBF-680 is an adenosine A1 receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral gelatine capsule
Study: NCT04560751

Intervention type: DRUG
Intervention: Lenvatinib
Description: Lenvatinib capsules will be administered orally, once daily (for patients \<60kg, lenvatinib 8mg po; for patients ≥60kg, lenvatinib 12mg po)

Intervention type: PROCEDURE
Intervention: TACE
Description: TACE will be performed as needed.
Study: NCT02371772

Intervention type: OTHER
Group type: OTHER
Intervention: Training
Description: Patients were trained to monitor INR and dose warfarin
Study: NCT01176461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1
Description: THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. MART-1:26-35(27L) peptide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1
Description: NY-ESO-1 peptide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100:209-217(210M)
Description: THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. gp100:209-217(210M) peptide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100:280-288(288V)
Description: gp100:280-288(288V) peptide vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558
Description: BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen \[HLA\] unrestricted)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BMS-936558
Description: BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen \[HLA\] unrestricted)
Study: NCT02475304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP187
Description: FP 187 is given as oral tablets twice daily, 500 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00334542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 24-28 weeks of simvastatin
Study: NCT02332304

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Preterm fetus
Description: A sample of amniotic fluid was taken before the birth of fetus between 26 and 36 6/7 weeks of pregnancy.